2. Search Result
Search Result
Pathways Recommended: Stem Cell/Wnt Cell Cycle/DNA Damage
Results for "

ovarian cancer cell

" in MedChemExpress (MCE) Product Catalog:

111

Inhibitors & Agonists

1

Screening Libraries

4

Peptides

7

Inhibitory Antibodies

18

Natural
Products

2

Isotope-Labeled Compounds

1

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N3415
    Kumatakenin
    1 Publications Verification

    		 Apoptosis Cancer
    Kumatakenin, a flavonoid that is isolated from cloves shows the effect of inducing apoptosis in ovarian cancer cells .
    Kumatakenin
  • HY-136528
    RA-9

    		Deubiquitinase Apoptosis Cancer
    RA-9 is a potent and selective proteasome-associated deubiquitinating enzymes (DUBs) inhibitor with favorable toxicity profile and anticancer activity. RA-9 blocks ubiquitin-dependent protein degradation without impacting 20S proteasome proteolytic activity. RA-9 selectively induces onset of apoptosis in ovarian cancer cell lines and primary cultures derived from donors. RA-9 induces endoplasmic reticulum (ER)-stress responses in ovarian cancer cells .
    RA-9
  • HY-P99463
    Batiraxcept

    AVB-S6-500

    		 TAM Receptor Cancer
    Batiraxcept (AVB-S6-500) is a highly potent and specific AXL inhibitor, a recombinant fusion protein dimer containing the extracellular domain of human AXLM and human immunoglobulin G1 heavy chain (Fc). Batiraxcept binds to GAS6 and inhibits the interaction of GAS6 with AXL, thereby substantially reducing AXL signaled invasion and migration of highly metastatic cells in vitro and inhibiting metastatic disease in nonclinical models of aggressive human cancers. Batiraxcept is available for studies in advanced or metastatic clear cell renal cell carcinoma (ccRCC) and platinum sensitive recurrent ovarian cancer .
    Batiraxcept
  • HY-112234
    L-Sepiapterin

    Sepiapterin

    		 Endogenous Metabolite Cancer
    L-Sepiapterin (Sepiapterin) is a precursor of the endothelial nitric oxide synthase (eNOS) cofactor tetrahydrobiopterin (BH4). L-Sepiapterin improves endothelial dysfunction in small mesenteric arteries from db/db mice, and induces angiogenesis. L-Sepiapterin inhibits cell proliferation and migration of ovarian cancer cells via down-regulation of p70 S6K-dependent VEGFR-2 expression .
    L-Sepiapterin
  • HY-N3446
    IVHD-valtrate

    		Apoptosis Cancer
    IVHD-valtrate, an active Valeriana jatamansi derivative, is against human ovarian cancer cells in vitro and in vivo. IVHD-valtrate induces cancer cells apoptosis and arrests the ovarian cancer cells in the G2/M phase. IVHD-valtrate has the potential to be a novel chemotherapeutic agent for the human ovarian cancer research .
    IVHD-valtrate
  • HY-149075
    MR22

    		Salt-inducible Kinase (SIK) Cancer
    MR22 is a potent pan-SIK (salt-inducible kinase) inhibitor. MR22 no longer exhibits activity on STE group kinases and displays excellent selectivity in a representative kinase panel. MR22-dependent SIK inhibition led to centrosome dissociation and subsequent cell-cycle arrest in ovarian cancer cells .
    MR22
  • HY-161253
    OSU-ERb-12

    		Estrogen Receptor/ERR Cancer
    OSU-ERb-12 is a ERβ agonist, and suppress ovarian cancer cell proliferation in vitro and in vivo. OSU-ERb-12 decreases the expression of Snail .
    OSU-ERb-12
  • HY-102073
    TG53

    		Glutaminase Integrin FAK Src Cancer
    TG53 is a potent inhibitor of tissue transglutaminase (TG2) and fibronectin (FN) protein-protein interaction. TG53 inhibits formation of a complex with integrin β1 and activation of FAK and c-Src during SKOV3 cell attachment onto FN. TG53 can be used for ovarian cancer research .
    TG53
  • HY-15519
    LBW242

    		IAP FLT3 Cancer
    LBW242, a 3-mer and Smac mimetic, is a potent and orally active proapoptotic IAP inhibitor. LBW242 shows effects on mutant FLT3-expressing cells. LBW242 has activity against multiple myeloma, and potentiates TRAIL- and anticancer agent-mediated cell death of ovarian cancer cells .
    LBW242
  • HY-123034
    CDKI-83

    		CDK Bcl-2 Family Apoptosis Cancer
    CDKI-83 is a potent CDK9 and CDK1 inhibitor with Ki values of 21 nM and 72 nM for CDK9/T1 and CDK1/B, respectively. CDKI-83 demonstrates effective anti-proliferative activity in human tumour cell lines with a GI50<1 μM. CDKI-83 effectively induces apoptosis in A2780 human ovarian cancer cells. CDKI-83 reduces phosphorylation at Ser-2 of RNA polymerase II (RNAPII) by inhibiting cellular CDK9 activity, and down-regulates Mcl-1 and Bcl-2. CDKI-83 has the potential for anti-cancer research .
    CDKI-83
  • HY-P99667
    Ipafricept

    OMP-54F28; FZD8-Fc

    		 Wnt Cancer
    Ipafricept (OMP-54F28; FZD8-Fc) is a first class recombinant fusion protein with the extracellular part of the human frizzled-8 receptor fused to a human IgG1 Fc fragment that binds Wnt ligands, which blocks Wnt signaling. Ipafricept reduces tumor growth and results in a decrease in both liver and lung metastases combined with Gemcitabine (HY-17026) in pancreatic cancer mouse models. Ipafricept shows solid tumor inhibition activity with well tolerance, such as desmoid tumor, germ cell cancer, ovarian cancer .
    Ipafricept
  • HY-163456
    Chx-HT

    		Apoptosis Cancer
    Chx-HT has an anti-proliferation activity and promotes apoptosis on ovarian cancer cells .
    Chx-HT
  • HY-127079
    Epothilone F

    		Microtubule/Tubulin Cancer
    Epothilone F is a Microtubule/Tubulin-stabilizing agent with anti-tumor activity. Epothilone F inhibits the proliferation of breast cancer cells, non-small cell lung cancer cells, drug-resistant ovarian cancer cells .
    Epothilone F
  • HY-E70295
    N-Acetylgalactosaminyltransferase 14

    GALNT14

    		 Endogenous Metabolite Cancer
    N-Acetylgalactosaminyltransferase 14 (GALNT14) is a mucin-type glycosylating enzyme polypeptide that promotes the migration of ovarian cancer by modifying mucin 13 (MUC13). GALNT14 can regulate the O-glycosylation and stability of MUC13, thereby mediating the malignant behavior of ovarian cancer cells .
    N-Acetylgalactosaminyltransferase 14
  • HY-117664
    PNR-7-02

    		Reverse Transcriptase Inflammation/Immunology
    PNR-7-02 inhibits Pol η function with an IC50 value of near 8 μM, which binds to the little finger domain. PNR-7-02 is also an inhibitor against hRev1 and hpol lambda (λ). PNR-7-02 acts synergistically with Cisplatin (HY-17394) to kill chronic myeloid leukaemia and ovarian cancer cell lines. PNR-7-02 is an indole thio-barbituric acid (ITBA) derivative with both N-napthoyl moiety and 5-chloro substituent on the indole ring .
    PNR-7-02
  • HY-155102
    PROTAC TG2 degrader-2

    		PROTACs Glutaminase Cancer
    PROTAC TG2 degrader-2 (compound 7) is a selective, competitive degrader targeting Transglutaminase 2 (TG2), with Kd > 100 μM. PROTAC TG2 degrader-2 inhibits the cell migration and decreases the level of TG2 in ovarian cancer cells. PROTAC TG2 degrader-2 can be used for ovarian cancer study .
    PROTAC TG2 degrader-2
  • HY-128595
    MT-4

    		Others Cancer
    MT-4 blocks the TG2/FN complex at the interface between cancer cells and the tumor niche. MT-4 inhibits the adhesion of ovarian cancer (OC) cells to the peritoneum .
    MT-4
  • HY-15184
    Elaiophylin

    Azalomycin B; Gopalamicin; Efomycin E

    		 Autophagy Antibiotic Cancer
    Elaiophylin (Azalomycin B; Gopalamicin; Efomycin E) is an autophagy inhibitor, exerts antitumor activity as a single agent in ovarian cancer cells .
    Elaiophylin
  • HY-N11010
    Eclalbasaponin IV

    		Others Cancer
    Eclalbasaponin IV is a triterpenoid that can be isolate from the aerial parts of Eclipta prostrata. Eclalbasaponin IV shows antitumor activity in human ovarian cancer cells .
    Eclalbasaponin IV
  • HY-103696
    PTC-028
    1 Publications Verification

    		 BMI1 Apoptosis Cancer
    PTC-028 is an orally bioavailable inhibitor of stem cell factor BMI-1 in ovarian cancer. PTC-028 selectively inhibits cancer cells whereas normal cells remain unaffected. PTC-028 downregulates BMI-1, inducing caspase-mediated apoptosis .
    PTC-028
  • HY-163743
    SIC-19

    		Salt-inducible Kinase (SIK) Cancer
    SIC-19 is a SIK2 inhibitor and promotes SIK2 protein degradation via the ubiquitination pathway. SIC-19 inhibits cancer cell growth and sensitizes cells to PARP inhibitors (Such as Olaparib (HY-10162)), as well as in ovarian cancer organoids and xenograft models .
    SIC-19
  • HY-147298
    Plogosertib
    1 Publications Verification

    CYC140

    		 Polo-like Kinase (PLK) Cancer
    Plogosertib (CYC140) is a selective, potent, and orally active ATP-competitive PLK1 inhibitor (IC50: 3 nM). Plogosertib is an anti-cancer agent with anti-proliferative activity. Plogosertib can be used in the research of several tumors, including esophageal, gastric, leukemia, non–small cell lung cancer, ovarian, and squamous cell cancers .
    Plogosertib
  • HY-P99592
    Solitomab

    AMG 110; MT110

    		 CD3 Cancer
    Solitomab (AMG 110) is a bispecific anti-CD3 and anti-epithelial-cell-adhesion-molecule (EpCAM) antibody. Solitomab can be used for the research of primary uterine and ovarian carcinosarcoma cancer .
    Solitomab
  • HY-151588
    Anticancer agent 90

    		Virus Protease Cancer
    Anticancer agent 90 is a benzothiazole-2-thiophene S-glycoside derivative with antitumor activity. Anticancer agent 90 has high inhibition against the two cell line from ovarian cancer (OVCAR-4), renal cancer (A498) .
    Anticancer agent 90
  • HY-P1103
    CTCE-9908
    1 Publications Verification

    		 CXCR Cancer
    CTCE-9908 is a potent and selective CXCR4 antagonist. CTCE-9908 induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .
    CTCE-9908
  • HY-157974
    [Ag(2,2′-bipy)(dppe)][CF3SO3]

    		Paraptosis Cancer
    [Ag(2,2′-bipy)(dppe)][CF3SO3] (compound 4) can induce cell paraptosis, and can be used for stusy of resistant ovarian cancer .
    [Ag(2,2′-bipy)(dppe)][CF3SO3]
  • HY-18652A
    Avutometinib potassium

    Ro 5126766 potassium; CH5126766 potassium

    		 Raf MEK Cancer
    Avutometinib (potassium) is a RAF/MEK clamp that potently inhibits RAF/MEK kinase activity and induces dominant negative RAF-MEK complexes preventing phosphorylation of MEK by ARAF, BRAF and CRAF. Avutometinib (potassium) shows anti-proliferative potency across tumor cell lines carrying KRAS mutations including PDAC cell lines. Avutometinib (potassium) induces tumor inhibition and increases survival in a KRAS/p53 pancreatic cancer mouse model. Avutometinib (potassium) is promising for research of low-grade-serous-ovarian-carcinoma (LGSOC), ovarian cancer and pancreatic ductal adenocarcinoma (PDAC) .
    Avutometinib potassium
  • HY-143253
    Estrogen receptor antagonist 7

    		Estrogen Receptor/ERR Cancer
    Estrogen receptor antagonist 7 (compound 13) is a potent estrogen receptors (ER) antagonist. Estrogen receptor antagonist 7 has antiproliferative activity against breast and ovarian cancer cells. Anticancer and anti-uterotrophic activities .
    Estrogen receptor antagonist 7
  • HY-139453
    LP-184

    		Others Cancer
    LP-184 (compound 6), an acylfulvene analog, inhibits tumor growth. LP-184 has potent anti-cancer activity in the ovarian, colon, prostate and pancreatic cell lines. (patent WO2007019308A2).
    LP-184
  • HY-116392B
    DL-threo-PDMP hydrochloride

    		Glucosylceramide Synthase (GCS) Cancer
    DL-threo-PDMP hydrochloride is the hydrochloride form of DL-threo-PDMP that is a competitive glucosylceramide synthase (GCS) inhibitor. DL-threo-PDMP resensitizes refractory testicular germ cell tumors and epithelial ovarian cancer orthoxenografts to cisplatin in mice .
    DL-threo-PDMP hydrochloride
  • HY-151587
    Anticancer agent 89

    		Others Cancer
    Anticancer agent 89 is a benzothiazole-2-thiophene S-glycoside derivative with antitumor activity, has high inhibition against the three cell line from ovarian cancer (OVCAR-4), renal cancer (A498), and melanoma (SK-MEL-5) .
    Anticancer agent 89
  • HY-19671
    Apomine

    SR-45023A; SR 9223i; SK&F-99085

    		 Apoptosis Cancer
    Apomine (SR-45023A) is an antineoplastic agent that inhibits the mevalonate/isoprenoid pathway in cholesterol synthesis. Apomine can accelerate the degradation of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR). Apomine can also inhibit the growth of various types of cancer cells, including lung cancer, colon cancer, breast cancer, and skin cancer. In addition, Apomine is able to induce apoptosis in tumor cell lines derived from leukemia, colon cancer, liver cancer, ovarian cancer, and breast cancer .
    Apomine
  • HY-P1103A
    CTCE-9908 TFA

    		CXCR Cancer
    CTCE-9908 TFA is a potent and selective CXCR4 antagonist. CTCE-9908 TFA induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .
    CTCE-9908 TFA
  • HY-123888
    Viomellein

    		Others Cancer
    Viomellein is an anticancer compound produced by the fungus Aspergillus ochraceus isolated from the Mediterranean sponge Agelas oroides. Viomellein exhibits cytotoxicity against A2780 human ovarian cancer cells with an IC50 value of 5.0 μM .
    Viomellein
  • HY-111538
    MAGL-IN-1

    		MAGL Cancer
    MAGL-IN-1 is a potent, selective, reversible and competitive inhibitor of MAGL, with an IC50 of 80 nM. MAGL-IN-1 exhibits anti-proliferative effects against human breast, colorectal, and ovarian cancer cells. MAGL-IN-1 blocks MAGL in cell-based as well as in vivo assays .
    MAGL-IN-1
  • HY-P99547
    Trastuzumab duocarmazine

    (vic)-Trastuzumab duocarmazine

    		 Antibody-Drug Conjugates (ADCs) Cancer
    Trastuzumab duocarmazine ((vic)-Trastuzumab duocarmazine) is a HER2-targeting ADC that is recognized and cleaved by histone B in tumor cells and selectively targets tumor cells. Trastuzumab duocarmazine has anti-tumor activity and can be used in cancer research related to uterine and ovarian sarcomas .
    Trastuzumab duocarmazine
  • HY-114250
    Cantrixil

    TRX-E-002-1

    		 Apoptosis Cancer
    Cantrixil (TRX-E-002-1), an active enantiomer of TRX-E-002, is a second-generation super-benzopyran (SBP) compound. Cantrixil increases phosphorylated c-Jun levels resulting in caspase-mediated apoptosis in ovarian cancer cells. Cantrixil has potent pan anti-cancer activity against a broad range of cancer phenotypes .
    Cantrixil
  • HY-119694
    Rotenolone

    		Others Cancer
    Rotenolone is an antiproliferative agent. Rotenolone shows antiproliferative activity against the ovarian cancer A2780, breast cancer BT-549, prostate cancer DU 145, NSCLC NCI-H460, and colon cancer HCC-2998 cell lines, with IC50s of 0.95, 1.6, 2.7, 2.0, and 2.9 μM, respectively .
    Rotenolone
  • HY-122650
    PHY34

    		Autophagy Cancer
    PHY34 is an inhibitor that inhibits ATP6V0A2 and CAS thereby inhibiting autophagy, and has a nanomolar effect. PHY34 inhibits cancer cell growth by inducing apoptosis and inhibits tumor growth in xenograft models. PHY34 can be used for research on high grade serous ovarian cancer .
    PHY34
  • HY-150231
    SU056

    		YB-1 Cancer
    SU056 is a YB-1 inhibitor. SU056 induces cell-cycle arrest, apoptosis, and inhibits cell migration in ovarian cancer cells. SU056 interacts with YB-1 and inhibits and its associated downstream proteins and pathways. SU056 can enhance the cytotoxic effects of Paclitaxel (HY-B0015) .
    SU056
  • HY-103359
    Ceranib1

    		Ceramidase Cancer
    Ceranib1 is a ceramidase inhibitor. Ceranib1 inhibits ceramidase activity toward an exogenous ceramide analog, induces the accumulation of multiple ceramide species, decreases levels of sphingosine and S1P. Ceranib1 inhibits the proliferation of ovarian cancer cells .
    Ceranib1
  • HY-19536
    LLL12

    		STAT Cancer
    LLL12 is a small molecule inhibitor of STAT3 that inhibits STAT3 phosphorylation. LLL12 enhanced the inhibitory effect of Cisplatin (HY-17394) and Paclitaxel (HY-B0015) on ovarian cancer cell formation, migration, and growth .
    LLL12
  • HY-P99506
    Tamrintamab

    SC-003 mAb; SC-Mab003; SC34.28ss1

    		 ADC Antibody Cancer
    Tamrintamab (SC-003 mAb, SC-Mab003, SC34.28ss1) is an ADC Antibody targeting to dipeptidase 3 (DPEP3 or MBD3). DPEP3 is a glycosyl phosphatidylinositol anchored metallopeptidase that is overexpressed in ovarian tumors. Tamrintamab can specifically bind DPEP3-expressing cells to produce cytotoxicity. Tamrintamab can be used in ovarian cancer research .
    Tamrintamab
  • HY-50936
    Trabectedin
    5 Publications Verification

    Ecteinascidin 743; ET-743

    		 Reactive Oxygen Species Apoptosis Inflammation/Immunology Cancer
    Trabectedin (Ecteinascidin 743; ET-743) is a tetrahydroisoquinoline alkaloid with potent antitumor activity. Trabectedin binds to the minor groove of DNA, blocks transcription of stress-induced proteins, induces DNA backbone cleavage and cancer cells apoptosis, and increases the generation of ROS in MCF-7 and MDA-MB-453 cells. Trabectedin has the potential for soft tissue sarcoma and ovarian cancer research .
    Trabectedin
  • HY-151972
    BRD4 Inhibitor-25

    		Epigenetic Reader Domain Cardiovascular Disease Inflammation/Immunology Cancer
    BRD4 Inhibitor-25 is a BRD4 inhibitor with IC50s of 0.82 μM, 1.94 μM for BD1 and BD2 domains of BRD4. BRD4 Inhibitor-25 induces apoptotic and autophagy cell death in ovarian cancer cells. BRD4 Inhibitor-25 can be used in the research of cancers, cardiovascular, neuromuscular and inflammatory disorders.
    BRD4 Inhibitor-25
  • HY-W021377C
    Exatecan Intermediate 4 dihydrochloride

    		ADC Cytotoxin Topoisomerase Cancer
    Exatecan Intermediate 4 dihydrochloride is an intermediate of Exatecan (DX-8951, HY-13631). Exatecan is an anticancer agent belonging to the class of camptothecin analogs. Exatecan interferes with the proliferation and division of tumor cells by interacting with DNA, thereby inhibiting tumor growth. Exatecan is primarily used for research of a variety of cancers including ovarian, lung and breast cancers .
    Exatecan Intermediate 4 dihydrochloride
  • HY-N1306
    Sideroxylin

    		Bacterial Reactive Oxygen Species Apoptosis Infection Cancer
    Sideroxylin is a C-methylated flavone isolated from Callistemon lanceolatus and exerts antimicrobial activity against Staphylococcus aureus. Sideroxylin inhibits ovarian cancer cell proliferation and induces apoptosis, causing DNA fragmentation, depolarization of the mitochondrial membrane, the generation of reactive oxygen species (ROS) .
    Sideroxylin
  • HY-W021377
    Exatecan Intermediate 2

    		ADC Cytotoxin Topoisomerase Cancer
    Exatecan Intermediate 2 (compound B) is an intermediate of Exatecan (DX-8951, HY-13631). Exatecan is an anticancer agent belonging to the class of camptothecin analogs. Exatecan interferes with the proliferation and division of tumor cells by interacting with DNA, thereby inhibiting tumor growth. Exatecan is primarily used for research of a variety of cancers including ovarian, lung and breast cancers .
    Exatecan Intermediate 2
  • HY-W021377A
    Exatecan Intermediate 2 hydrochloride

    		ADC Cytotoxin Topoisomerase Cancer
    Exatecan Intermediate 2 hydrochloride (compound B) is an intermediate of Exatecan (DX-8951, HY-13631). Exatecan is an anticancer agent belonging to the class of camptothecin analogs. Exatecan interferes with the proliferation and division of tumor cells by interacting with DNA, thereby inhibiting tumor growth. Exatecan is primarily used for research of a variety of cancers including ovarian, lung and breast cancers .
    Exatecan Intermediate 2 hydrochloride
  • HY-W021377B
    Exatecan Intermediate 4

    		ADC Cytotoxin Topoisomerase Cancer
    Exatecan Intermediate 4 (compound B) is an intermediate of Exatecan (DX-8951, HY-13631). Exatecan is an anticancer agent belonging to the class of camptothecin analogs. Exatecan interferes with the proliferation and division of tumor cells by interacting with DNA, thereby inhibiting tumor growth. Exatecan is primarily used for research of a variety of cancers including ovarian, lung and breast cancers .
    Exatecan Intermediate 4

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: